Cognition Therapeutics Inc.
CGTX | NASDAQ
$1.01
+$0.01 (+1.00%)
Sep 22, 2026, 12:01 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | 235K | n/a | 98K |
Gross Profit | n/a | n/a | n/a | -235K | n/a | -98K |
Operating Income | -47.8M | -53.97M | -50.72M | -43.55M | -28.6M | -17.41M |
Interest Income | n/a | n/a | 24.81M | 22.22M | 17.45M | 10.86M |
Pretax Income | -23.49M | -33.97M | -25.79M | -21.4M | -11.72M | -7.84M |
Net Income | -23.49M | -33.97M | -25.79M | 757K | -11.72M | -10.07M |
Selling & General & Admin | 10.61M | 12.29M | 13.53M | 13.23M | 10.03M | 4.52M |
Research & Development | 37.19M | 41.68M | 37.2M | 30.32M | 18.57M | 12.89M |
Other Expenses | n/a | n/a | n/a | -235K | n/a | -98K |
Operating Expenses | 47.8M | 53.97M | 50.72M | 43.32M | 28.6M | 17.31M |
Interest Expense | 13K | 25K | 27K | 28K | 893K | 1.75M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 47.8M | 53.97M | 50.72M | 43.55M | 28.6M | 17.41M |
Income Tax Expense | n/a | n/a | n/a | -22.15M | n/a | n/a |
Shares Outstanding (Basic) | 72.77M | 39.73M | 29.99M | 28.99M | 22.23M | 21.94M |
Shares Outstanding (Diluted) | 72.77M | 39.73M | 30.03M | 28.99M | 22.23M | 21.94M |
EPS (Basic) | -0.32 | -0.85 | -0.86 | -0.74 | -0.73 | -0.55 |
EPS (Diluted) | -0.32 | -0.85 | -0.86 | -0.74 | -0.73 | -0.55 |
EBITDA | -23.25M | -33.68M | -25.51M | -21.13M | -10.73M | -5.99M |
EBIT | -23.47M | -33.95M | -25.76M | -21.37M | -10.82M | -6.09M |
Depreciation & Amortization | 228K | 266K | 252K | 235K | 93K | 98K |
Add to Watchlist
Select watchlists to add or remove CGTX